Compare · VVOS vs WST
VVOS vs WST
Side-by-side comparison of Vivos Therapeutics Inc. (VVOS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both VVOS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.96B, about 5616.4x VVOS ($4.8M).
- Over the past year, VVOS is down 95.5% and WST is up 39.7% - WST leads by 135.1 points.
- VVOS has been more active in the news (4 items in the past 4 weeks vs 3 for WST).
- WST has more recent analyst coverage (20 ratings vs 1 for VVOS).
- Company
- Vivos Therapeutics Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $4.8M
- $26.96B
- 1M return
- -28.14%
- +4.70%
- 1Y return
- -95.45%
- +39.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 3
- Recent ratings
- 1
- 20
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest VVOS
- SEC Form 8-K filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
- Vivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
- SEC Form 4 filed by Director Sokolow Leonard J
- SEC Form 4 filed by Director Johnson Gregg C
- Chief Executive Officer Huntsman Ronald Kirk acquired $50,000 worth of Preferred Stock (85,910 units at $0.58) (SEC Form 4)
- Amendment: Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Vivos Therapeutics Announces Material Debt Reduction
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences